Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;43(7):877-88.

Association between β2-Adrenergic Receptor-16Arg/Gly Gene Polymorphism and Chronic Obstructive Pulmonary Disease Risk:Systematic Review and Meta-Analysis

Affiliations
Free PMC article
Review

Association between β2-Adrenergic Receptor-16Arg/Gly Gene Polymorphism and Chronic Obstructive Pulmonary Disease Risk:Systematic Review and Meta-Analysis

Wei Wang et al. Iran J Public Health. 2014 Jul.
Free PMC article

Abstract

Background: The association between β2-adrenergic receptor (ADRB2) -16Arg/Gly polymorphism (rs1042713) and chronic obstructive pulmonary disease (COPD) risk has been investigated in many published studies. However, the results were inconclusive. A meta-analysis was performed to make a more precise estimation of the relationship.

Methods: The PubMed, EMBASE, ISI web of science, the Cochrane Database of Systematic Reviews, and Chinese databases (CNKI, Wanfang Data, CBM, VIP) were searched for published literature. Odds ratios (OR) with 95% confidence interval (CI) were used to assess the strength of association.

Results: Eleven studies, comprising 1,128 COPD patients and 1,182 controls, were included in the meta-analysis. Overall, there was no significant association between the ADRB2-16Arg/Gly polymorphism and COPD risk in general population. In the stratification analysis by potential confounding variables, significant associations were observed between the ADRB2-16Arg/Gly polymorphism and COPD risk among smoking Asians under the dominant genetic model and allele model (Arg vs. Gly) (dominant model: OR = 1.45, 95% CI = 1.04-2.01, P = 0.311 for heterogeneity, z = 2.22, P = 0.026 for OR; allele model: OR = 1.27, 95% CI = 1.03-1.57, P = 0.209 for heterogeneity, z = 2.20, P = 0.028 for OR), but not in other subgroups.

Conclusion: This meta-analysis suggested that the ADRB2-16Arg/Gly polymorphism might be a potential risk factor for the development of COPD in smoking Asian populations, but not in European descendents, and tobacco smoking probably increased the genetic susceptibility. More studies with larger sample sizes are needed to validate the results.

Keywords: COPD; Meta-analysis; Tobacco smoking; rs1042713; β2-adrenergic receptor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of the meta-analysis
Fig. 2
Fig. 2
Forest plot for the association between ADRB2-16Arg/Gly and COPD risk under the dominant genetic model. High heterogeneity was existing among studies and the random-effects model was performed
Fig. 3
Fig. 3
Forest plot for the association between ADRB2-16Arg/Gly and COPD risk among smoking Asians under allele and dominant genetic models. (A) dominant model, (B) allele model, fixed-effects model was used
Fig. 4
Fig. 4
Sensitivity analysis for the association between the ADRB2-16Arg/Gly polymorphism and COPD risk among smoking Asians. Each circle and transverse line represented the pooled OR and 95% CI by deleting the corresponding study
Fig. 5
Fig. 5
Begg’s funnel plot for publication bias of studies under dominant model. Each circle represented a corresponding study

Similar articles

Cited by

References

    1. Vestbo J, Hurd SS, Agusti AGet al. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 187(4): 347–65. - PubMed
    1. Yamaya A, Osanai K (2011). [Cytokines and proteases involved in pathogenesis of COPD]. Nihon Rinsho Japanese Journal of Clinical Medicine, 69(10): 1748–53. - PubMed
    1. Sethi JM, Rochester CL (2000). Smoking and chronic obstructive pulmonary disease. Clin Chest Med, 21(1): 67–86. - PubMed
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC (2002). Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. MMWR Surveill Summ, 51(6): 1–16. - PubMed
    1. Sandford AJ, Silverman EK (2002). Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax, 57(8): 736–41. - PMC - PubMed